IMO, COGS is not the issue, the issue is the admin and gen. expenses, and I believe to some extent a big part of that is R&D.
We have a product that is FDA cleared being sold in numerous countries, and there is almost no marketing, yet we're spending a lot on R&D. I understand that further development must be done to improve the device, but IMO it's more important to market the heck out of the current device, let it gain some traction and use the money from sales for R&D.
I understand that it's up to the OEMs to pursue the marketing of the device, but when they slack off in that department BIEL can't just simply sit back and hope for the best!
"Did you not listen to KN state that BIEL now operates with 7 employees?"
2022 sales expense 6mos. 116k R&D 143k
2021 " " 251k " " 327k
2020 " " 367k " " 483k
2019 " " 329k " " 658k
Reduce the employees and shift the money to R&D?